REVISE: Galderma To Meet with FDA About Rx-to-OTC Acne Switch

Galderma Laboratories, L.P. has submitted an application to the FDA in support of the over-the-counter (OTC) marketing of adapalene gel 0.1%, currently a prescription drug.
 
According to Kline & Company, this could be game changer for the acne category, which is crowded with various skin care brands and products ranging from OTC acne medications to facial treatments to prescription acne medications.
 
Recording nearly 7% growth in 2014, the market for acne medications in the United States is largely made up of teens, but also a growing adult acne consumer group with the ability to pay higher price points to treat their acne, according to a recently published Acne Care Market in the United States report from Kline & Company.  Consumers view mass-market products as effective for treating mild acne; however, they also seek professional treatments and prescription drugs from physicians to treat severe to chronic acne conditions.
 
According to the American Academy of Dermatology, about 40 to 50 million Americans suffer from acne.
 
With such a growing consumer market of both adults and teens suffering from acne, Kline notes there is an increasing demand for acne products with interest across various market segments and product types, including both topical medications and skin care devices.
 
Product innovations for acne treatment play an important role and serve to reinvigorate and reshape the market, generating larger consumer interest.
 
To understand what drugs and ingredients may eventually make their way to the OTC market, Kline’s Rx-to-OTC Switch Pipelines: Competitive Assessment provides a thorough overview of this category by profiling various companies engaged in marketing prescription acne medications, including Actavis, Galderma Laboratories, GlaxoSmithKline/Novartis, and Valeant Pharmaceuticals. Medications such as Aczone, Differin, Epiduo, Duac, Veltin, and Acanya are also analyzed.
 
According to Kline, topical prescription medications are often easier for marketers to gain FDA approval for OTC sales since they are not systemically absorbed like oral medications. The availability of one or more of these drugs without a prescription would bring innovation and improvements to existing OTC products to the market, further driving strong sales growth within the acne market.
 
In order to compete in such a multi-faceted market, the Acne Care Market in the United States, Beauty Devices: Global Market Analysis and Opportunities, Professional Skin Care Global Series, and Rx-to-OTC Switch Pipelines: Competitive Assessment reports will help you understand the competitive landscape, evaluate sales through various channels of distribution and brands, capitalize on new trends and developments, as well as forecast sales and growth and future Rx-to-OTC switches that will have significant impacts on the market.